© 2014 Informa UK Ltd. This provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. DISCLAIMER: The ideas and opinions expressed in the journal’s Just Accepted articles do not necessarily reflect those of Informa Healthcare (the Publisher), the Editors or the journal. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in these articles. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosages, the method and duration of administration, and contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Just Accepted articles have undergone full scientific review but none of the additional editorial preparation, such as copyediting, typesetting, and proofreading, as have articles published in the traditional manner. There may, therefore, be errors in Just Accepted articles that will be corrected in the final print and final online version of the article. Any use of the Just Accepted articles is subject to the express understanding that the papers have not yet gone through the full quality control process prior to publication. Just Accepted by Current Medical Research & Opinion Brief Report Use of a urea, arginine and carnosine cream versus a standard emollient glycerol cream for treatment of severe xerosis of the feet in patients with Type 2 diabetes: A randomized, 8-month, assessor- blinded, controlled trial Adalberto Federici, Giovanni Federici, Massimo Milani doi: 10.1185/03007995.2015.1037731 Abstract Background: No long-term data are available regarding effects of emollients in treating severe foot skin xerosis in patients with diabetes. Study Aim: We evaluated the efficacy of 8-month urea, arginine and carnosine cream (UC) in comparison with a glycerin-based emollient cream (SEC), in type 2 patients with diabetes, who had severe feet xerosis. Subjects and Methods: We assessed the effect of UC and SEC on skin hydration in a randomized, assessor-blinded study in 50 patients treated with UC (N=25) or SEC (N=25) for 32 weeks with a twice-daily application. Primary outcomes were a 9-point Xerosis-Assessment-Scale (XAS) score and a 4-point Overall-Cutaneous-Score (OCS), evaluated at baseline, after 4-12-32 weeks. Skin hydration and desquamation were also objectively evaluated by means of a bio-impedance skin analysis device (Hydr8*) at baseline and at week 32. Results: UC induced greater hydration than SEC (p=0.001) with a 91% reduction at week 32 in XAS score vs. baseline. After 4 weeks, compared with the SEC treated group, XAS score in UC treated group was significantly lower. OCS was reduced by 27% from baseline to end of the study in UC group, and increase by 8% in the SEC group (P=0.02; between groups). At month 8, skin hydration and desquamation evaluated by the digital skin analysis system statistically improved in UC treated subjects in comparison with baseline and SEC group values. This study was not double-blind. In order to overcome this problem we performed an assessor-blinded evaluation of the primary endpoints and using an objective measurement tool for skin hydration and desquamation assessment. Conclusion: A 8-month urea, arginine and carnosine cream increases skin hydration and improves skin dryness in Type 2 diabetic patients in comparison with a glycerol-based emollient cream with a greater efficacy observed as soon as 4 weeks of treatment. Curr Med Res Opin Downloaded from informahealthcare.com by IBI Circulation - Ashley Publications Ltd on 04/09/15 For personal use only.